Ticker
ABBV

Price
145.02
Stock movement down
-0.18 (-0.12%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
256.46B
Ent value
369.93B
Price/Sales
4.44
Price/Book
16.00
Div yield
4.08%
Div growth
17.11%
Growth years
9
FCF payout
44.94%
Trailing P/E
19.13
Forward P/E
12.35
PEG
2.31
EPS growth
36.80%
1 year return
3.05%
3 year return
18.74%
5 year return
4.72%
10 year return
14.58%
Last updated: 2023-02-06

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.92
Dividend yield4.08%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.73%
Minimum yield3.16%
Discount to avg yield-15.86%
Upside potential-13.69%
Yield as % of max yield55.78%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.08%
Current yield distribution71.27%
Yield at 100% (Min)3.16%
Yield at 90%3.71%
Yield at 80%3.95%
Yield at 50% (Median)4.80%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.92
Payout frequencyQuarterly
Ex-div date12 Jan 2023
EPS (TTM)7.55
EPS (1y forward)11.74
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR4.96%11.59%
DGR TTM7.53%10.54%
DGR 3 years9.63%4.00%
DGR 5 years17.11%5.65%
DGR 10 years-7.37%
DGR 15 years-5.83%
Time since last change announced103 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM73.48%44.94%
Average--
Forward50.43%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E19.13
Price to OCF11.35
Price to FCF11.70
Price to EBITDA10.14
EV to EBITDA14.62

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.44
Price to Book16.00
EV to Sales6.40

FINANCIALS

Per share

Loading...
Per share data
Current share count1.77B
EPS (TTM)7.55
FCF per share (TTM)12.34

Income statement

Loading...
Income statement data
Revenue (TTM)57.82B
Gross profit (TTM)40.26B
Operating income (TTM)17.69B
Net income (TTM)13.41B
EPS (TTM)7.55
EPS (1y forward)11.74

Margins

Loading...
Margins data
Gross margin (TTM)69.62%
Operating margin (TTM)30.59%
Profit margin (TTM)23.19%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash11.83B
Net receivables10.74B
Total current assets30.36B
Goodwill31.73B
Intangible assets68.72B
Property, plant and equipment0.00
Total assets141.32B
Accounts payable23.50B
Short/Current long term debt69.61B
Total current liabilities32.71B
Total liabilities125.30B
Shareholder's equity16.03B
Net tangible assets-84.46B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)22.59B
Capital expenditures (TTM)669.00M
Free cash flow (TTM)21.92B
Dividends paid (TTM)9.85B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity83.65%
Return on Assets9.49%
Return on Invested Capital15.66%
Cash Return on Invested Capital25.60%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open145.74
Daily high146.33
Daily low144.81
Daily Volume3.77M
All-time high174.96
1y analyst estimate162.50
Beta0.62
EPS (TTM)7.55
Dividend per share5.92
Ex-div date12 Jan 2023
Next earnings date9 Feb 2023

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-17.11%-14.21%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.22%-11.49%
Avg time to new high17 days13 days
Max time to new high975 days1805 days
COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
256.46B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Would you like a stock portfolio that generates enough passive income to fuel your retirement dreams? Unlike most areas of the economy, healthcare services are a top priority in good economic times a...
February 7, 2023
AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
February 6, 2023
Chief Executive Officer Richard Gonzalez said the company now has the capacity "to do more", in an interview with WSJ that was published on Monday. Abbvie is hoping to replace the loss of revenue fro...
February 6, 2023
The drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost.
February 6, 2023
In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy Acco...
February 5, 2023
AbbVie Inc. ( NYSE:ABBV ) shareholders have seen the share price descend 13% over the month. But don't let that...
February 5, 2023
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adr...
February 4, 2023
Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laborator...
February 4, 2023
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
February 3, 2023
Revance Therapeutics and RVNC stock are in rarified positions after the FDA approved the company's new treatment for frown lines.
February 3, 2023
Next page